|Bid||202.54 x 800|
|Ask||204.11 x 800|
|Day's Range||200.81 - 204.12|
|52 Week Range||166.30 - 211.90|
|Beta (3Y Monthly)||0.79|
|PE Ratio (TTM)||16.10|
|Earnings Date||Oct 29, 2019|
|Forward Dividend & Yield||5.80 (2.85%)|
|1y Target Est||216.00|
During Alexion's (ALXN) third-quarter earnings call, investor focus will be on the sales performance of its blockbuster drug Soliris along with the sales figure of Ultomiris, Strensiq and Kanuma.
THOUSAND OAKS, Calif., Oct. 18, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) approved Amgen's Supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) to include new data in its U.S. prescribing information showing sustained platelet responses in adults with immune thrombocytopenia (ITP), a rare, serious autoimmune disease characterized by low platelet counts. The updated indication expands treatment with Nplate to newly diagnosed and persistent adult ITP patients who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 17) Applied Therapeutics Inc (NASDAQ: APLT ) Arrowhead ...
THOUSAND OAKS, Calif. and BRUSSELS, Oct. 17, 2019 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced that following a re-examination procedure, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending Marketing Authorization for EVENITY® (romosozumab) for the treatment of severe osteoporosis in postmenopausal women at high risk of fracture and with no history of myocardial infarction or stroke. EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss).
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Alexion says it will acquire clinical-stage startup Achillion Pharmaceuticals Inc. for $930 million upfront.
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Sanofi has invested $1.5 billion into expanding over the last five years as it competes with companies like new CEO Paul Hudson’s former company Novartis Corp.
THOUSAND OAKS, Calif., Oct. 15, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the expansion of Myeloma MVP™, a national initiative to help myeloma patients and their care teams create their Most Valuable Plan. In its second year, Myeloma MVP now includes an updated tool on MyelomaExplained.com to help patients communicate with their doctors and develop a personal strategy for managing their disease. College football anchor Rod Gilmore, who was diagnosed with multiple myeloma in July 2016, is partnering with Amgen Oncology as part of this year's Myeloma MVP team.
Sen. Elizabeth Warren’s health-care reform crusade is rattling biotech investors — but that’s not the industry’s only problem, writes Michael Brush.
Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they allocate a lot of time and employ complex research processes to determine the best stocks to invest in. A particularly […]
THOUSAND OAKS, Calif. and PITTSBURGH, Oct. 9, 2019 /PRNewswire/ -- The Amgen Foundation today announced the launch of the Amgen Biotech Experience (ABE) program in Pittsburgh, Pa. Through a grant from the Richard King Mellon Foundation, the region's students will become a part of the Amgen Foundation's respected international science education program, making it the tenth program site in the United States and the 20th worldwide.
Houston’s largest publicly traded company by revenue, Phillips 66 (NYSE: PSX), has a new independent director — former Walmart Inc. (NYSE: WMT) CFO Charles Holley. Phillips 66, which owns and operates downstream and midstream assets, tapped Holley for the job Oct. 4, and he will hold his seat on the board of directors until the next annual shareholder meeting in 2020, according to a company filing with the U.S. Securities and Exchange Commission.
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. The price hikes were more than twice the rate of medical inflation and were not supported by any new clinical evidence, the Institute for Clinical and Economic Review (ICER) said in the analysis.